Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05732272 · ClinicalTrials.gov registry record · Phase 3
Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment
A Phase 3 study of Smoking Cessation, sponsored by University of Kansas Medical Center.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 500
- Enrollment target
- 1
- Study location
NCT05732272 is a Phase 3 study of Smoking Cessation that is actively recruiting participants, run by University of Kansas Medical Center. The registered enrollment target is 500 participants, roughly in line with the 472-participant average among 188 other Smoking Cessation trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT05732272, a Phase 3 study of Smoking Cessation, is actively recruiting participants, sponsored by University of Kansas Medical Center.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the efficacy of extended bupropion(6 months) versus standard bupropion treatment (7 weeks) among African American daily smokers.
Conditions Studied
Interventions
- DRUG Bupropion
Study Locations (1)
Missouri
- University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2023-02-28 |
| Est. Completion | 2027-04-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05732272
The ClinicalTrials.gov registry entry for NCT05732272 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 472-participant average among 188 other Smoking Cessation trials with a reported enrollment target. The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Smoking Cessation appearing as the primary indexed condition, and to 1 intervention - of which Bupropion is the first listed.
NCT05732272 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT05732272 about?
NCT05732272 is a clinical study titled "Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment". This study will evaluate the efficacy of extended bupropion(6 months) versus standard bupropion treatment (7 weeks) among African American daily smokers.
What is the current status of trial NCT05732272?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 500 participants. The study started on 2023-02-28. Estimated completion is 2027-04-30.
What conditions does trial NCT05732272 study?
This clinical trial studies the following conditions: Smoking Cessation.
What interventions are being tested in trial NCT05732272?
The interventions under investigation include: Bupropion (DRUG).
Who is sponsoring clinical trial NCT05732272?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05732272 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tobacco Education and Lung Health Study (TEAL)
RECRUITING · Phase 3
-
V+PSF-M for Tobacco Cessation in HIV Care in India
RECRUITING · Phase 3
-
Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype
COMPLETED · Phase 3
-
Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).
COMPLETED · Phase 3
-
Safety and Efficacy Study of Topiramate to Aid in Smoking Cessation
COMPLETED · Phase 3
-
Nicotine Mouth Film for Craving Relief.
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.